Expansion Opportunity The production block expansion in Hyderabad India increases capacity for oral solid dosage forms and APIs, signaling a potential upsell for contract manufacturing, formulation development, and fill-finish services to support higher volumes and new product launches.

Pipeline Growth Recent launches including Edoxaban and Apremilast tablets in Europe indicate a growing portfolio across anticoagulant and inflammatory segments, presenting cross-sell opportunities for packaging, regulatory support, and regional distribution partnerships.

Strategic Partnerships Active collaboration with Neuraxpharm for Tegomil Fumarate in Germany demonstrates appetite for alliance-driven market entry, suggesting opportunities to propose co-development, co-commercialization, or regional distribution agreements.

Global Footprint With global presence, own labs and multiple manufacturing sites, there is potential to position Tiefenbacher as a trusted API and finished dosage form supplier for prospective customers seeking end-to-end supply chain resilience.

Industry Engagement Participation in CPHI events and ongoing European launches indicate a readiness to expand in key markets; sales teams can target regional pharma players with needs for scalable manufacturing, regulatory registration support, and portfolio expansion.